Table 1: Properties and efficacy
of commonly used and upcoming anti-addiction drugs.
NT system |
Existing and potential
pharmacotherapies |
References |
Dopamine system ·
Normalization of DAergic response ·
Alcohol drinking ·
Adjuvant treatment for the withdrawal
symptoms (WS) |
Dopamine receptor partial agonists ·
Aripiprazole - D2 receptor partial
agonists ·
Bromocriptine
- WS adjuvant therapy |
Brunetti, et al. Kenna, et al.
Williams and McBride [147-150]. |
Dopamine receptor antagonists ·
GSK
598809 - D3 receptor antagonists |
Te
Beek, et al. [151]. |
|
GABA system ·
Prevents
relapse ·
Suppresses
the WS |
GABA receptor modulators ·
Gabapentin
- GABAB receptor modulator ·
Benzodiazepines |
Karam-Hage
and Brower, |
5-HT systems ·
Decrease in craving and drinking |
Selective
serotonin uptake inhibitor ·
Fluoxetine, Sertraline, Citalopram ·
5-HT
antagonist ondansetron |
Naranjo,
et al. Gerra, Babor and Caetano,
Dundon, et al. Johnson [154-159]. |
Brain stress system ·
Stress management ·
Manage alcohol drinking ·
Prevents relapse ·
Reduce alcohol drinking ·
Adjuvants for the WS |
CRF-related targets ·
Antalarmin,
pexacerfont - CRF receptor antagonists |
|
Non-CRF-related targets ·
Prazosin
- α1 Adrenergic receptor antagonist ·
Naltrexone/β-Funaltrexamine - µ
opioid receptor antagonists ·
Norbinaltorphimine - κ opioid receptor antagonist ·
Naltrindole - d opioid receptor antagonist ·
Nalmefen - µ and d opioid receptor antagonist |
Rasmussen, et al. Volpicelli, et al. Kranzler,
et al. Matsuzawa, et al. Krishnan-Sarin, et al. Froehlich, et al. [162-168]. |
|
·
Neuropeptide
Y receptor agonist ·
(Leu31Pro34
NPY) ·
Substance
P receptor antagonist ·
L-760735 |
||
Glutamate system ·
Increases
duration of ·
Abstinence ·
Reduces
drinking and facilitates ·
Abstinence ·
Alcohol
dependence and ·
Drinking |
Glutamate receptor agonists and
antagonists ·
Acamprosate - N-methyl-D-aspartate
(NMDA) receptor partial agonist ·
Topiramate
- α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor
antagonist ·
3-[(2-methyl-1,3-thiazol-4-yl)
ethynyl] pyridine (MTEP)mGluR5
antagonist. |
Kranzler and Gage,
Kranzler, et al. Johnson, et al. Johnson, Weiss and Porrino, Blednov
and Harris [34,171-176]. |
Stress management and alcohol
craving |
·
LY-379,268
- mGluR2 and mGluR3 agonist ·
(1S,2R,5R,6R)-2-amino-4-oxabicyclo
[3.1.0]hexane-2,6-dicarboxylic acid |
Zhao and Wu [177]. |
Antipsychotic activity |
Aripiorazole |
Wang,
et al. [61]. |